









Up-regulation of miR-130b expression level
and down-regulation of miR-218 serve as
potential biomarker in the early detection
of human osteosarcoma
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Abstract
Background: Osteosarcoma (OS) is a primary malignant bone tumor with high morbidity that principally emerges in
children and adolescents. MiRNAs regulate a variety of normal physiologic processes and are involved in tumorigenesis
and development of multiple malignancies, including OS. This study was aimed to evaluate the clinical significance of
miR-130b and miR-218 in osteosarcoma patient.
Methods: We utilized quantitative real-time PCR to evaluate the level of miR-130b and miR-218 expressions in OS
patients and normal tissues and their relationship with clinicopathological features and survival in OS patients.
Results: QRT-PCR indicated that miR-130b expression in tumor tissues was strongly elevated than adjacent non-tumor
tissues (P < 0.001), while the level of miR-218 expression in osteosarcoma tissues was down-regulated than adjacent
non-tumor tissues (P < 0.001). We evaluated the clinical significance of miR-130b and miR-218 in osteosarcoma. Clinical
correlation analysis showed that increased expression of miR-130b and decreased expression of miR-218 were
significantly associated with advanced tumor stage (x2 = 6.285, P < 0.009; x2 = 7.172, P < 0.007), distant metastasis
(x2 = 5.528; P < 0.001; x2 = 4.617, P < 0.001) and size of tumor (x2 = 5.01, P = 0.013; x2 = 4.271, P = 0.019).
Conclusions: Taken together, our data indicated that high miR-130b level and low level of miR-218 are associated
with poor clinicopathological characteristics. Furthermore, miR-130b may play a key role in the progression of
osteosarcoma.
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Background
Osteosarcoma (OS) is a primary malignant bone tumor
with high morbidity in children and young adults; hat is
more common in males than in females [1–4]. Despite
current treatments combining chemotherapy, surgery,
the 5-year cumulative survival rate of primary osteosar-
coma was only 50 %–60 % [5, 6]. Therefore, the discov-
ery of new biomarkers for the diagnosis, prognosis, and
treatment of OS remains an important but unmet clin-
ical need. miRNAs are a family of small, non-coding,
endogenous RNAs, that inhibit gene expression by bind-
ing to the 3′untranslated region (3′-UTR) of mRNA se-
quence, leading to translational degradation or repression
[7, 8]. Studies have also shown that miRNAs are involved
in tumor genesis and cancer progression. MiRNAs can
function as either tumor suppressors or oncogenes ac-
cording to their target genes [9, 10]. Many miRNAs are
deregulated in various cancer subtypes [11–14].
MiRNAs have been indicated to be correlated with the
proliferation, differentiation, apoptosis and invasion of
tumor cells [15]. However, the role of miRNAs in osteo-
sarcoma development has only recently been investigated
and further investigations are needed to clarify the role
miRNAS in terms of osteosarcoma. MiR-130b has been
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studied in various types of human cancers [16–20].
Down-regulation of miR-130b has been reported in
endometrial cancer, pituitary adenomas, papillary thy-
roid carcinoma, and pancreatic cancer [18–21].
Nevertheless, it has been shown that miR-130b ex-
pression was aberrantly increased in melanoma, colo-
rectal cancer, bladder cancer, and gastric carcinoma
[16, 17, 22–24].
MiR-218 has been reported to be significantly deregu-
lated in many kinds of tumors [25–30]. It was down-
regulated in lung, prostate, cervical, colon, gastric, blad-
der cancer and hepatocellular carcinoma [25–29]. More-
over, decreased expression of miR-218 was related to a
significant worse survival of HCC patients. Down regula-
tion of miR-218 was found in osteosarcoma tissues [31].
Moreover, it has been reported that miR-218 inhibited
osteosarcoma cell migration and invasion by down-
regulating T-cell lymphoma invasion and metastasis 1
(TIAM1), matrix metalloproteinase2 (MMP2) and MMP9
[31]. However, it is important to evaluate the clinical
significance of miR-130b and miR-218 in osteosarcoma
patients.
Materials and methods
Ethical approval for the study was obtained according to
the Declaration of Helsinki. All subjects were volunteers
and informed consents were obtained.
Patients and tissue specimens
Cancerous tissues and adjacent non-tumor tissues
(>3 cm distance to the resection margin) were ob-
tained from 30 patients who underwent curative re-
section of osteosarcoma between December 2007 and
September 2013 in Mashhad and Tabriz hospitals,
Iran. All clinical samples were used after obtaining in-
formed consent. Moreover, histological subtype and
tumor grade were determined using the World Health
Organization (WHO) criteria (Fig. 1). The tissues were
stored at −80 °C until use. Union for International
Cancer Control (UICC) tumor-nodemetastases (TNM)
Staging Classification was used for the staging of the
tumor. The clinical features of all enrolled patients were
shown in Table 1.
RNA extraction and qRT-PCR
Briefly, total RNA was extracted from the tissues using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA), accord-
ing to the manufacturer’s instructions. Two microliters
of cDNA obtained from each sample was amplified and
quantified by real-time PCR of TaqMan Human MiRNA
Assay (Applied Biosystems) according to the manufac-
turer’s protocol. MiRNAs expressions relative to U6
were evaluated using the comparative cycle threshold
(CT) method.
Statistical analysis
The GraphPad Prism 5 software (GraphPad Software, Inc.,
San Diego, CA, USA) was applied for chi-square test and
Two-tailed Student’s t test. Differences were considered
statistically significant when p was less than 0.05.
Results and Discussion
QRT-PCR indicated that miR-130b expression in tumor
tissues was strongly elevated than adjacent non-tumor
tissues (1.04 ± 0.31 vs. 0.59 ± 0.12, P < 0.001; Fig. 2), while
the level of miR-218 expression in osteosarcoma tissues
was down-regulated than adjacent non-tumor tissues
(0.61 ± 0.21 vs. 1.53 ± 0.42, P < 0.001; Fig. 2).
We evaluated the clinical significance of miR-130b
and miR-218 in osteosarcoma. Clinical correlation
analysis showed that increased expression of miR-
130b and decreased expression of miR-218 were sig-
nificantly associated with advanced tumor stage (x2 =
6.285, P < 0.007; x2 = 7.172, P < 0.009), distant metasta-
sis (x2 = 5.528; P < 0.001; x2 = 4.617, P < 0.001) and size
of tumor (x2 = 5.01, P = 0.013; x2 = 4.271, P = 0.019),
(Table 1).
These results suggested that high miR-130b level and
low level of miR-218 are associated with poor clinico-
pathological characteristics.
There is growing evidence that miRNAs can act as ei-
ther oncogenes or tumor suppressor, depending on their
target genes. Dysregulation of miRNAs has been linked
to different malignancies [32, 33]. It has been already re-
ported that different kinds of miRNAs are up-regulated
or underexpressed in OS tissues and cell lines. These
miRNAs are involved in occurrence and development of
many kinds of tumors [34]. Down-regulation of miR-
130b has been documented in endometrial cancer, pitu-
itary adenomas, papillary thyroid carcinoma, and pan-
creatic cancer [18–21]. On the other hand, it was shown
that miR-130b expression was increased in melanoma,
colorectal cancer, bladder cancer, and gastric carcinoma
[16, 17, 22–24]. Our findings indicated that miR-130b
expression was strongly elevated in tumor tissues when
compared with adjacent non-tumor tissues. Clinical cor-
relation analysis showed that increased expression of
miR-130b was significantly associated with advanced
Fig. 1 Expression levels of miR-130b and miR-218 in osteosarcoma
tissues and adjacent non-tumor tissues









tumor stage, distant metastasis and size of tumor. These
results suggested that high miR-130b level is associated
with poor clinicopathological characteristics. Elevated
expression level of miR-130b was associated with poorer
prognosis of osteosarcoma patients. A previous study in-
dicated that in CRC miR-130b induces EMT through a
pathway that appears to be independent of DICER1 and
its downstream target miR-200c. Moreover, the PPARγ
is as a direct functional target of miR-130b in colorectal
cancer. PPARγ is a CRC-independent prognostic factor
implicated in cell differentiation and suppression of cell
growth likely through up-regulation of its target genes
E-cadherin, p21, and PTEN in colorectal cancer [17]. It
has been found that, miR-130b could contribute to EMT
Table 1 Association between the clinicopathological parameters and expression of miRNAs in the osteosarcoma patients
Clinicopathological features No. of cases Expression of miR-130b Expression of miR-218 P value of miR-130b P value of miR-218
Low = 11 High = 19 Low = 17 High = 13
Gender 0.741 0.712
Male 17 7 10 11 6
Female 13 4 9 6 7
Age 0.517 0.483
<24 12 4 8 7 5
≥25 18 7 11 10 8
Tumor diameter (cm) 0.013 0.019
≤6 16 9 7 6 10
>6 14 2 12 11 3
Histology 0.51 0.503
Conventional osteosarcoma 20 6 14 11 9
Others 10 5 5 6 4
Clinical stage 0.009 0.007
I 12 8 4 4 8
II 10 3 7 6 4
III 8 0 8 7 1
Distant metastasis <0.001 <0.001
No 18 8 10 7 11
Yes 12 3 9 10 2
Fig. 2 Pathology of osteosarcomas. High-powered photomicrographs of human osteosarcomas show condensation of the neoplastic cells (H&E)









of cancer cells by targeting DICER1 [35]. The involve-
ment of miR-130b in CRC-related angiogenesis and
EMT has been previously shown. In hypoxic conditions,
miR-130b represses DDX6 leading to increased activity
of HIF1α, a well-known VEGF inducer.
Furthermore, deregulation of miR-218 was reported in
many kinds of tumors [25–30]. Down-regulation of it
has been found in lung, prostate, cervical, colon, gastric,
bladder cancer and hepatocellular carcinoma [25–29].
Moreover, decreased expression of miR-218 was related
to a significant worse survival of HCC patients. Down
regulation of miR-218 was found in osteosarcoma tissues
[31]. Moreover, it has been reported that miR-218 inhib-
ited osteosarcoma cell migration and invasion by down-
regulating T-cell lymphoma invasion and metastasis 1
(TIAM1), matrix metalloproteinase2 (MMP2) and
MMP9 [31]. In the present study, the level of miR-218
expression in osteosarcoma tissues was down-regulated
in comparison with adjacent non-tumor tissues. We
evaluated the clinical significance of miR-218 in osteo-
sarcoma. Clinical correlation analysis showed that
decreased expression of miR-218 was significantly asso-
ciated with advanced tumor stage, distant metastasis and
size of tumor. These results suggested that low level of
miR-218 is associated with poor clinicopathological
characteristics.
It has been reported that the low level of miR-218 is asso-
ciated with TNM stage, lymph node metastasis and histo-
logical differentiation in colon cancer. Moreover, patients
with low miR-218 expression had shorter survival in colon
cancer [27]. Lower level of miR-218 has been found in pa-
tients with large tumor size and advanced TNM tumor
stage in hepatocellular carcinoma tissues [30]. Our findings
suggested that that miR-218 may be a potential marker in
osteosarcoma patients. A previous study indicated that
LEF1 is a new direct target of miR-218, and miR-218 can
reduce protein levels of LEF1 and MMP-9 in glioblastoma
cells. They hypothesized that miR-218 can directly target
LEF1, resulting in reduced synthesis of MMP-9. Moreover,
they concluded that miR-218 is involved in the invasive be-
havior of GBM cells and by targeting LEF1 and blocking
the invasive axis, miR-218-LEF1-MMPs, it may be useful
for developing potential clinical strategies [36]. Jin et al.
[31] indicated that miR-218 can act as inhibitor of osteosar-
coma cell migration and invasion by down-regulating
TIAM1, MMP2 and MMP9 expression [18]. However,
further studies are needed to clarify the role of miR-218 in
osteosarcoma cell proliferation and apoptosis.
Conclusions
In summary, our data indicated that high miR-130b level
and low level of miR-218 are associated with poor clini-
copathological characteristics. Furthermore, miR-130b
may play a key role in the progression of osteosarcoma.
Abbreviations
OS: Osteosarcoma; 3′-UTR: 3′untranslated region; CT: Cycle threshold;
UICC: Union for International Cancer Control; WHO: World Health
Organization; TNM: Tumor-nodemetastases; TIAM1: T-cell lymphoma invasion
and metastasis1; MMP2: Matrix metalloproteinase2.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AT, AJT, MJ, MSH, SKH and EY participated in sample collection and processing
and coordination and helped to draft the manuscript and data analyses and
manuscript preparation. MSH participated in design of the study and writing.
The authors read and approved the final manuscript.
Acknowledgements
We gratefully thank Dr. Javanbakht in providing the diagnosis of bone neoplasms
with histological interpretation and for his editorial and administrative assistance
and his scientific review in the preparation of this article.
Author details
1Department of Orthopedics Surgery, Tehran Medical Sciences Branch,
Islamic Azad University, Tehran, Iran. 2Department of Genetics, Faculty of Life
Sciences, Azad University of Tehran Medical Sciences Branch, Tehran, Iran.
3Cellular and Molecular Research Center, Zahedan University of Medical
Sciences, Zahedan, Iran. 4Department of Clinical Biochemistry, School of
Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
5Department of Orthopaedic and Trauma Surgery, Birjand University of
Medical Sciences, Birjand, Iran. 6Department of Statistics, Faculty of Sciences,
Islamic Azad University, Mashhad Branch, Mashhad, Iran. 7Department of
Molecular Biology, Baqiyatallah University of Medical Sciences, Tehran, Iran.
8Graduate, Faculty of Medicine, Tehran University of Medical Sciences,
Tehran, Iran.
Received: 11 August 2015 Accepted: 1 October 2015
References
1. Tang J, Shen L, Yang Q, Zhang C. Overexpression of metadherin mediates
metastasis of osteosarcoma by regulating epithelial-mesenchymal transition.
Cell Prolif. 2014;47(5):427–34.
2. Montanaro L, Mazzini G, Barbieri S, Vici M, Nardi-Pantoli A, Govoni M.
Different effects of ribosome biogenesis inhibition on cell proliferation in
retinoblastoma protein- and p53-deficient and proficient human
osteosarcoma cell lines. Cell Prolif. 2007;40(4):532–49.
3. Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma. Curr Opin
Pharmacol. 2014;16C:15–23.
4. Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in
osteosarcoma. Pharmacol Ther. 2013;137:89–99.
5. Thayanithy V, Park C, Sarver AL, Kartha RV, Korpela DM, Graef AJ.
Combinatorial treatment of DNA and chromatin-modifying drugs cause cell
death in human and canine osteosarcoma cell lines. PLoS One.
2012;7(9):e43720.
6. Hu H, Zhang Y, Cai XH, Huang JF, Cai L. Changes in microRNA expression in
the MG-63 osteosarcoma cell line compared with osteoblasts. Oncol Lett.
2012;4(5):1037–42.
7. Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical
implications in Ewing’s sarcoma. Cell Prolif. 2015;48(1):1–6.
8. Yu X, Li Z. MicroRNAs regulate vascular smooth muscle cell functions in
atherosclerosis (review). Int J Mol Med. 2014;34(4):923–33.
9. Hirata H, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y. Oncogenic
miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS
One. 2012;7(11):e51056.
10. Liu G, Jiang C, Li D, Wang R, Wang W. MiRNA-34a inhibits EGFR-signaling-
dependent MMP7 activation in gastric cancer. Tumour Biol.
2014;35(10):9801–6.
11. Shah NR, Chen H. MicroRNAs in pathogenesis of breast cancer: Implications
in diagnosis and treatment. World J Clin Oncol. 2014;5:48–60.
12. Drusco A, Nuovo GJ, Zanesi N, Di Leva G, Pichiorri F, Volinia S, et al.
MicroRNA profiles discriminate among colon cancer metastasis. PLoS One.
2014;9:e96670.









13. D’Anzeo M, Faloppi L, Scartozzi M, Giampieri R, Bianconi M, Del Prete M, et
al. The role of micro-RNAs in hepatocellular carcinoma: from molecular
biology to treatment. Molecules. 2014;19:6393–406.
14. Kang SM, Lee HJ. MicroRNAs in human lung cancer. Exp Biol Med
(Maywood). 2014;239(11):1505–13.
15. Chang SJ, Weng SL, Hsieh JY, Wang TY, Chang MD, Wang HW. MicroRNA-
34a modulates genes involved in cellular motility and oxidative
phosphorylation in neural precursors derived from human umbilical cord
mesenchymal stem cells. BMC Med Genet. 2011;4:65.
16. Lai KW, Koh KX, Loh M, Tada K, Subramaniam MM. MicroRNA-130b regulates
the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer.
2010;46(8):1456–63.
17. Colangelo T, Fucci A, Votino C, Sabatino L, Pancione M. MicroRNA-130b
promotes tumor development and is associated with poor prognosis in
colorectal cancer. Neoplasia. 2013;15(10):1218–31.
18. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H. Mutant p53
gain-of-function induces epithelial-mesenchymal transition through
modulation of the miR-130b-ZEB1 axis. Oncogene. 2013;32(27):3286–95.
19. Leone V, Langella C, D’Angelo D, Mussnich P, Wierinckx A, Terracciano L.
Mir-23b and miR-130b expression is downregulated in pituitary adenoma.
Mol Cellular Endocrinol. 2014;390(1–2):1–7.
20. Zhao G, Zhang JG, Shi Y, Qin Q, Liu Y, Wang B. MiR-130b is a prognostic
marker and inhibits cell proliferation and invasion in pancreatic cancer
through targeting STAT. PLoS One. 2013;8(9):e73803.
21. Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE. MicroRNA
signature distinguishes the degree of aggressiveness of papillary thyroid
carcinoma. Ann Surg Oncol. 2011;18(7):2035–41.
22. Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn SA.
Comparative microarray analysis of microRNA expression profiles in primary
cutaneous malignant melanoma, cutaneous malignant melanoma
metastases, and benign melanocytic nevi. Cell Tissue Res. 2013;351(1):85–98.
23. Kim BH, Hong SW, Kim A, Choi SH, Yoon SO. Prognostic implications for
high expression of oncogenic microRNAs in advanced gastric carcinoma.
J Surg Oncol. 2013;107(5):505–10.
24. Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Muller SC, Ellinger
J. Circulating microRNAs in serum: novel biomarkers for patients with
bladder cancer? World J Urol. 2014;32(2):353–8.
25. Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL, Yao GL. Reduced expression of
circulating microRNA-218 in gastric cancer and correlation with tumor
invasion and prognosis. World J Gastroenterol. 2014;20(22):6906–11.
26. Davidson MR, Larsen JE, Yang IA, Hayward NK, Clarke BE, Duhig EE. MicroRNA-
218 is deleted and downregulated in lung squamous cell carcinoma. PLoS
One. 2010;5(9):e12560.
27. He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK. MicroRNA-218 inhibits cell
cycle progression and promotes apoptosis in colon cancer by downregulating
BMI1 polycomb ring finger oncogene. Mol Med. 2013;18:1491–8.
28. Nishikawa R, Goto Y, Sakamoto S, Chiyomaru T, Enokida H, Kojima S.
Tumor-suppressive microRNA-218 inhibits cancer cell migration and
invasion via targeting of LASP1 in prostate cancer. Cancer Sci.
2014;105(7):802–11.
29. Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H.
MiR-218 on the genomic loss region of chromosome 4p15.31 functions as a
tumor suppressor in bladder cancer. Int J Oncol. 2011;39(1):13–21.
30. Tu K, Li C, Zheng X, Yang W, Yao Y, Liu Q. Prognostic significance of
miR-218 in human hepatocellular carcinoma and its role in cell growth.
Oncol Rep. 2014;32(4):1571–7.
31. Jin J, Cai L, Liu ZM, Zhou XS. MiRNA-218 inhibits osteosarcoma cell migration
and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J
Cancer Prev. 2013;14(6):3681–4.
32. Bottai G, Pasculli B, Calin GA, Santarpia L. Targeting the microRNA-
regulating DNA damage/repair pathways in cancer. Expert Opin Biol Ther.
2014;14(11):1667–83.
33. Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of
MicroRNAs in cancer. Curr Biol. 2014;24:R762–76.
34. Nugent M. MicroRNA function and dysregulation in bone tumors: the
evidence to date. Cancer Manag Res. 2014;6:15-25
35. Li BL, Lu C, Lu W, Yang TT, Qu J, Hong X. MiR-130b is an EMT-related
microRNA that targets DICER1 for aggression in endometrial cancer. Med
Oncol. 2013;30(1):484.
36. Liu Y, Yan W, Zhang W, Chen L, You G, Bao Z. MiR- 218 reverses high
invasiveness of glioblastoma cells by targeting the oncogenic transcription
factor LEF1. Oncol Rep. 2012;28(3):1013–21.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Taheriazam et al. Diagnostic Pathology  (2015) 10:184 Page 5 of 5
